Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2016; 05(02): 056-058
DOI: 10.4103/2278-330X.181626
METRONOMIC THERAPY IN HEAD AND NECK CANCERS : Original Article

Metronomic palliative chemotherapy in maxillary sinus tumor

Vijay M. Patil
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vanita Noronh
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Ashay Karpe
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vikas Talreja
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Arun Chandrasekharan
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Sachin Dhumal
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: Metronomic chemotherapy consisting of methotrexate and celecoxib recently has shown promising results in multiple studies in head and neck cancers. However, these studies have not included patients with maxillary sinus primaries. Hence, the role of palliative metronomic chemotherapy in patients with maxillary sinus carcinoma that is not amenable to radical therapy is unknown. Methods: This was a retrospective analysis of carcinoma maxillary sinus patients who received palliative metronomic chemotherapy between August 2011 and August 2014. The demographic details, symptomatology, previous treatment details, indication for palliative chemotherapy, response to therapy, and overall survival (OS) details were extracted. SPSS version 16 was used for analysis. Descriptive statistics have been performed. Survival analysis was done by Kaplan-Meier method. Results: Five patients had received metronomic chemotherapy. The median age was 60 years (range 37-64 years). The proportion of patients surviving at 6 months, 12 months, and 18 months were 40%, 40%, and 20%, respectively. The estimated median OS was 126 days (95% confidence interval 0-299.9 days). The estimated median survival in patients with an event-free period after the last therapy of <6 months was 45 days, whereas it was 409 days in patients with an event-free period postlast therapy above 6 months (P = 0.063). Conclusion: Metronomic chemotherapy in carcinoma maxillary sinus holds promise. It has activity similar to that seen in head and neck cancers and needs to be evaluated further in a larger cohort of patients.

Key words

Chemotherapy - head and neck cancer - maxilla - metronomic - palliative


Publication History

Article published online:
28 December 2020

© 2016. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Dubal PM, Bhojwani A, Patel TD, Zuckerman O, Baredes S, Liu JK, et al. Squamous cell carcinoma of the maxillary sinus: A population-based analysis. Laryngoscope 2016;126:399-404.
  • 2 Kumar V, Sindhu VA, Rathanaswamy S, Jain J, Pogal JR, Akhtar N, et al. Cancers of upper gingivobuccal sulcus, hard palate and maxilla: A tertiary care centre study in North India. Natl J Maxillofac Surg 2013;4:202-5.
  • 3 Noronha V, Patil VM, Joshi A, Krishna MV, Dhumal S, Juvekar S, et al. Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus. Chemother Res Pract 2014;2014:487872.
  • 4 Qureshi SS, Chaukar DA, Talole SD, D′Cruz AK. Squamous cell carcinoma of the maxillary sinus: A Tata Memorial Hospital experience. Indian J Cancer 2006;43:26-9.
  • 5 McMahon JD, Wong LS, Crowther J, Taylor WM, McManners J, Devine JC, et al. Patterns of local recurrence after primary resection of cancers that arise in the sinonasal region and the maxillary alveolus. Br J Oral Maxillofac Surg 2013;51:389-93.
  • 6 Zylka S, Zawadzki M, Postula S, Bien S. Recurrence of cancer of the paranasal sinuses after primary treatment - Analysis of conditions and results of salvage treatment. Otolaryngol Pol 2010;64:44-9.
  • 7 Parikh P, Patil V, Agarwal JP, Chaturvedi P, Vaidya A, Rathod S, et al. Guidelines for treatment of recurrent or metastatic head and neck cancer. Indian J Cancer 2014;51:89-94.
  • 8 Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21 Suppl 7:vii252-61.
  • 9 Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
  • 10 Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Bhosale B, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015;51:279-86.
  • 11 Patil V, Noronha V, Krishna V, Joshi A, Prabhash K. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers. Clin Oncol (R Coll Radiol) 2013;25:388.
  • 12 Patil VM, Noronha V, Joshi A, Pinninti R, Dhumal S, Bhattacharjee A, et al. Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian J Med Paediatr Oncol 2015;36:161-5.